<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04679597</url>
  </required_header>
  <id_info>
    <org_study_id>ERID-KSOPKR-0009/2019</org_study_id>
    <nct_id>NCT04679597</nct_id>
  </id_info>
  <brief_title>Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure</brief_title>
  <official_title>Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Oncology Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Oncology Ljubljana</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a retrospective study, the investigators will compare patients with locally advanced&#xD;
      rectal cancer with high risk factors for failure who were treated with standard therapy or&#xD;
      with total neoadjuvant therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>pathological complete response</measure>
    <time_frame>during surgery</time_frame>
    <description>pathological complete response is defined as the absence of tumor cells in the surgical resection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neoadjuvant rectal cancer score</measure>
    <time_frame>during treatment, assessed up to 10 days</time_frame>
    <description>Neoadjuvant rectal cancer score: The NAR score was calculated using the equation [5 pN - 3(cT - pT) + 12]^2 / 9.61 and further classified as low (&lt; 8), intermediate (8-16), or high (&lt; 16).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>number of participants who completed treatment</measure>
    <time_frame>during treatment, assessed up to 10 days</time_frame>
    <description>Compliance - number of participants who completed treatment protocol</description>
  </other_outcome>
  <other_outcome>
    <measure>number of participants with acute side effects</measure>
    <time_frame>during treatment, assessed up to 10 days</time_frame>
    <description>Acute toxcity - number of participants with side effects during different treatment modality</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">161</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>total neoadjuvant therapy</arm_group_label>
    <description>Total neoadjuvant therapy consisted of 12 weeks of induction chemotherapy with CAPOX or FOLFOX, chemoradiotherapy with capecitabine and six to eight weeks of consolidation chemotherapy with CAPOX or FOLFOX prior to surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard therapy</arm_group_label>
    <description>Standard therapy (neoadjuvant chemoradiotherapy, surgery, adjuvant chemotherapy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>comparison of two treatments</description>
    <arm_group_label>standard therapy</arm_group_label>
    <arm_group_label>total neoadjuvant therapy</arm_group_label>
    <other_name>oxaliplatin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all adult patients with newly diagnosed LARC with high risk factors for failure who were&#xD;
        treated with TNT or standard therapy at the Institute of Oncology, Ljubljana, from 2016 to&#xD;
        2019&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically proven locally advanced rectal cancer and&#xD;
&#xD;
          -  the presence of one of the factors: T4, N2, positive mesorectal fascia, presence of&#xD;
             extramural vascular invasion or presence of lateral lymph node.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  distant metastases,&#xD;
&#xD;
          -  concomitant malignancy,&#xD;
&#xD;
          -  inflammatory bowel disease, or&#xD;
&#xD;
          -  malabsorption syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

